Prime Medicine Inc

For the period ended Dec 31, 2023. Filed Mar 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 1, 2024

PRME$3.90-9.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss F-

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Year Ended December 31,
(in thousands, except share and per share amounts)	2023	2022
Operating expenses:
Research and development (1)	$147,905	$86,725
Settlement payment — related party	13,500	—
General and administrative	43,387	29,819
Total operating expenses	204,792	116,544
Loss from operations	(204,792)	(116,544)
Other income (expense):
Change in fair value of short-term investment — related party	(2,382)	(8,128)
Other income, net	8,762	1,903
Total other income (expense), net	6,380	(6,225)
Net loss before income taxes	(198,412)	(122,769)
Benefit from income taxes	279	948
Net loss	$(198,133)	$(121,821)
Cumulative dividend on preferred stock	—	(20,193)
Net loss attributable to common stockholders	$(198,133)	$(142,014)
Net loss per share attributable to common stockholders, basic and diluted	$(2.18)	$(4.19)
Weighted-average common shares outstanding, basic and diluted	90,969,327	33,891,264
Comprehensive loss:
Net loss	$(198,133)	$(121,821)
Change in unrealized loss on investments, net of tax	369	(357)
Comprehensive loss	$(197,764)	$(122,178)

(1)Includes related party amounts of $0.6 million and $0.7 million for the years ended December 31, 2023 and 2022, respectively.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.